Atrial Fibrillation - Drug Pipeline Landscape, 2023

Atrial Fibrillation - Drug Pipeline Landscape, 2023

Atrial fibrillation is a type of cardiac arrhythmia acclaimed by an anomalous cardiac rhythm element by a disturbance in heart’s electrical system. There are three types of atrial fibrillation Paroxysmal atrial fibrillation, Persistent atrial fibrillation, Long-standing persistent atrial fibrillation.

Causes of atrial fibrillation are augmentation of blood clots within the upper chambers of the heart and age, heart disease, high blood pressure, family history and drinking alcohol.

Symptoms include decreased blood pressure, weakness, lightheadedness, confusion and chest pain.

Atrial fibrillation is diagnosed by electrocardiogram (ECG or EKG), blood tests, holter monitor, chest X-ray.

Atrial fibrillation is treated by lifestyle changes and drugs like potassium channel blockers, beta-blockers and calcium channel blockers.

There are many clinical trials currently ongoing in atrial fibrillation drug development. Some of the most promising trials are studying new ways to prevent or treat atrial fibrillation, including new drugs, devices, and surgical procedures. Many of these trials are still in the early stages, but they offer hope for better treatments for this common and potentially deadly condition.

Major pharmaceutical companies are involved in the development of potential drug candidates to improve the treatment of Atrial Fibrillation treatment such as Xeomin, Abelacimab, HSY244, and others. Key players involved in the development of therapies to treat Atrial Fibrillation are AbbVie Inc, Bayer, Novartis, and others. Two drugs are under Phase III clinical trials and 10+ drugs are in Phase II clinical trials and some other drugs are under Phase I, preclinical and discovery stages of development.

Report Highlights

Global Insight Service’s, Atrial Fibrillation - Drug Pipeline Landscape, 2023 report provides an overview of the Atrial Fibrillation pipeline drugs. This report covers detailed insights on Atrial Fibrillation drugs under development, assessment by target, mechanism of action, route of administration and molecule type. Product pipeline by companies, stage of development and key regulatory designations, deals and milestones have been presented to provide insights and thus help industry participants in their decision making. Atrial Fibrillation pipeline report helps gain insights on drugs which are under development stage of drug development process across globally.

Methodology

The research process includes extensive secondary research on public domain and other authentic sources to add or update the pipeline products information. The secondary research sources include, but are not limited to company websites, annual reports, financial reports, company pipeline chart, investor presentations and SEC filings, journals and conferences, and clinical trials registries.

Scope

The pipeline landscape report provides analysis of pipeline products based on several stages of development ranging from Discovery to Pre-Registration. The report provides a review of pipeline therapeutics by companies based on information derived from company and industry-specific sources. The pipeline report covers assessment of therapeutics by mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. Comprehensive profiles of the pipeline products with details such as company overview, development stage; molecule type, target, mechanism of action, route of administration, dosage form, regulatory designations, key deals, clinical trials, and key upcoming milestones are included.

Reasons to Buy
Helps to find and recognize significant therapeutics under development. Thorough understanding of pipeline structure and helps in developing corrective measures for pipeline projects.
Effective R&D strategies can be developed with deep knowledge of competitor information, analysis, and insights.
Plan collaborations with various industry partners that have role in some or the other stage of drug development such as contract manufacturing, co-development, contract research organization and commercialization etc.
Helps to create in-licensing and out-licensing opportunities by identifying prospective partners with attractive projects to expand business potential and scope.

Please Note: This report will be delivered by publisher within 3-4 business days of order confirmation.